3 results
Approved WMOWill not start
Primary: Safety and tolerability of 2 dosages of ambrisentan. Secundary: Efficacy and PK.
Approved WMOWill not start
Primary: Longterm safety and tolerability of 2 dosages of ambrisentan. Secundary: Supportive efficacy data.
Approved WMOCompleted
The primary objective of this study is to evaluate the blood pressure control rate after 12 weeks of treatment with telmisartan/amlodipine FDC in patients who were previously not controlled on RAAS blocking mono-therapy (ARBs, ACEi, DRI).